PM
CCXI

Parametrica Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Parametrica Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,976
Closed -$286K – 170
2020
Q2 		$286K Buy
+4,976
New +$271K 0.31% 83

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Parametrica Management's CCXI Position: Q3 2020 in Review

Parametrica Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2020, closing a stake of 4,976 shares — an estimated $286K sold.

Parametrica Management first reported a position in CCXI in Q2 2020 and held it in 1 quarter. The position peaked at $286K in Q2 2020. 204 funds tracked by Wall St. Rank hold CCXI as of Q3 2020.

  • Parametrica Management reported no remaining ChemoCentryx, Inc. position as of Q3 2020 after selling out during the quarter.
  • Parametrica Management sold 4,976 ChemoCentryx, Inc. shares in Q3 2020, an estimated $286K.
  • Parametrica Management first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 1 quarter.
  • Parametrica Management's ChemoCentryx, Inc. position peaked at $286K in Q2 2020.
  • 204 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2020.

Based on Parametrica Management's 13F filing for Q3 2020, filed 13 Nov 2020.